We also note that a recent study in CCA showed that combination of the dual PI3K/mTOR inhibitor BEZ235 with JQ1 showed efficacy in vitro and in vivo through inhibiting c-Myc and YAP (34). This evidence concerns the gene MYC and cholangiocarcinoma.